Close Menu

More articles about Business, Policy & Funding

The firm brought in $15.8 million during the quarter compared to $8.8 million a year ago, and beating Wall Street expectations.

The firm offered more than 2.7 million shares of its common stock, including 356,435 shares to its underwriters pursuant to an option to purchase additional shares.

The firm it plans to offer from time to time units of its common stock, preferred stock, one or more debt securities, warrants, or rights to such securities in one or more series.

The company missed the analysts' average estimates on the top and bottom lines, but it raised its full-year 2019 revenue guidance.

Buoyed by a 26 percent increase in test volume, the firm's revenues were $1.2 million for the quarter, compared to $822,000 last year.

Among the claims, NeuMoDx has alleged that BD was kept up to date on the firm's technology as it was developed and that one of the patents was duplicitously expanded by BD.

The company is delaying the publication of its business and financial update for the first half of 2019 to allow for an ongoing review by its auditors.

Onconova will use Mission Bio's Tapestri platform to study rigosertib — a drug that Onconova is developing — to target the RAS mutation in myelodysplastic syndromes.

The firm said its platform provides sample-to-answer results for two of the most frequently tested sexually transmitted infections, enabling rapid testing and treatment.

The company said it is pushing to begin simultaneous clinical trials for multiple small panel-based tests for its sample-to-answer Savanna platform.

The firm expects to use proceeds from the offering to expand its life sciences commercial operations, and improve and update its Simoa technology and instruments, among other initiatives.

The firm experienced a 30 percent jump in sales of immunoassays, attributed in part to a $6.2 million increase in influenza revenues year-over-year.

NantHealth's net loss fell by 37 percent, to $14.7 million, as revenue from software-related revenue jumped by 23 percent while expenses fell.

The San Diego-based genome mapping company attributed the drop in revenues to fewer international sales of its Saphyr platform.

The company is on track to submit Guardant360 to the FDA in the third quarter, but also expects to see pan-cancer reimbursement much sooner.

The company expects the rollout of more reliable, user-friendly platforms will increase instrument usage among a substantial segment of its customer base.

The Gaithersburg, Maryland-based company continues to await US Food and Drug Administration clearance for its antimicrobial resistance test.

LineaRx was formed last year to commercialize Applied DNA Sciences' technologies for DNA design, manufacture, and chemical modification by large scale PCR.

Quanterix intends to grant underwriters a 30-day option to purchase up to an additional 15 percent of the shares of common stock at the public offering price.

The company attributed the revenue decline to a 96 percent drop in licensing revenues, which more than offset a 36 percent increase in product sales.

Pages

Holden Thorp is to be the new editor-in-chief of Science and its related journals.

A genetic analysis of salmon scales collected over the course of a century points to a sharp decline in the number of fish returning each year to river in British Columbia, CBC reports.

Adelaide University has suspended the head of an ancient DNA lab as its investigation of workplace bullying continues, Australia's ABC News reports.

In PNAS this week: gene expression profiles of adipocyte subtypes, computational approach for improving plant expressome analysis, and more.